Hap Trading, LLC Editas Medicine, Inc. Transaction History

Hap Trading, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 12, 2022	BUY	$14.08 - $27.63 $155,513 - $305,173	11,045 Added 42.83%	36,831 $701,000
Q4 2021 Feb 14, 2022	SELL	$26.55 - $40.57 $65,897 - $100,694	-2,482 Reduced 8.78%	25,786 $685,000
Q3 2021 Nov 10, 2021	BUY	$39.27 - $72.94 $164,344 - $305,253	4,185 Added 17.38%	28,268 $1.16 Million
Q1 2021 May 14, 2021	BUY	$39.71 - $90.58 $482,794 - $1.1 Million	12,158 Added 101.95%	24,083 $1.01 Million
Q4 2020 Feb 16, 2021	SELL	$27.07 - $84.35 $541 - $1,687	-20 Reduced 0.17%	11,925 $836,000
Q1 2020 May 08, 2020	BUY	$14.88 - $32.78 $22,825 - $50,284	1,534 Added 14.73%	11,945 $237,000
Q3 2019 Nov 12, 2019	SELL	$22.49 - $26.81 $167,010 - $199,091	-7,426 Reduced 41.63%	10,411 $237,000
Q2 2019 Aug 14, 2019	SELL	$20.48 - $27.76 $198,246 - $268,716	-9,680 Reduced 35.18%	17,837 $441,000
Q1 2019 May 10, 2019	BUY	$19.43 - $26.41 $534,655 - $726,723	27,517 New	27,517 $673,000

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Hap Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Hap Trading, LLC with notifications on news.